Telesis Bio, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric Esser
- Full Time Employees
- 39
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 29 Hartwell Ave Lexington MA United States of America 92121-2993
- IPO Date
- Jun 18, 2021
- CIK
- 0001693415
- Website
- codexdna.com
- Similar Companies
- Business
- Telesis Bio, Inc., a synthetic biology innovator, develops and distributes automated multi-omic and synthetic biology solutions. The company supplies sophisticated instruments, reagents, and associated services, primarily serving pharmaceutical, academic, and government research entities globally, alongside contract research organizations and other synthetic biology enterprises. Among its key solutions are the BioXp® systems, offered in models like the BioXp 3250 and 9600, which empower researchers to quickly generate endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) directly from digital sequences, often incorporating onboard next-generation sequencing library preparation. The BioXp portal provides an intuitive online environment with guided workflows and design functionalities for building novel DNA sequences, assembling them into desired vectors, and developing mRNA constructs. Complementing these systems, BioXp kits supply crucial building blocks and reagents, including the specialized Gibson Assembly® branded reagents, for various synthetic biology workflow applications such as cloning, mRNA generation, and cell-free amplification. The company also features its Gibson SOLA™ Enzymatic Synthesis platform, delivering non-toxic, high-fidelity, and scalable methods for rapid on-site DNA and mRNA synthesis. Further offerings include benchtop reagents tailored for specific synthetic biology processes utilizing BioXp system-generated products, and Biofoundry Services, enabling customers to order and receive finished BioXp system output, such as genes, clones, and variant libraries. The company, initially known as Codex DNA, Inc., officially transitioned to Telesis Bio, Inc. in November 2022. Founded in 2011, Telesis Bio, Inc. is headquartered in San Diego, California.
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results
Telesis Bio Reports First Quarter 2024 Financial Results
Telesis Bio Announces Reverse Stock Split
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
Why Is Telesis Bio (TBIO) Stock Up 29% Today?
Telesis Bio Reports Third Quarter 2023 Financial Results
Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
Telesis Bio Appoints William J. Kullback Chief Financial Officer
Telesis Bio, Inc. (TBIO) Q2 2023 Earnings Call Transcript
Telesis Bio Reports Second Quarter 2023 Financial Results
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
Telesis Bio to Present at Jefferies Healthcare Conference 2023
Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
Telesis Bio to Present at SynBioBeta 2023